Topical montelukast formulations
AssigneeTaro Pharmaceutical Industries Ltd.
InventorsVered ROSENBERGER, Helena SHIFRIN, Irena OLEINIK, Tzviel SHESKIN, Ron SCHLINGER, Avi AVRAMOFF
Life of this patent
Estimating the term…
Loading patent…
AssigneeTaro Pharmaceutical Industries Ltd.
InventorsVered ROSENBERGER, Helena SHIFRIN, Irena OLEINIK, Tzviel SHESKIN, Ron SCHLINGER, Avi AVRAMOFF
Estimating the term…
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.
A topical emulsion comprising
A method of treating atopic dermatitis, erythema, pruritus or combinations thereof comprising topically administering a stable formulation comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof, wherein the formulation is stable for at least 2 weeks.
A method of reducing IGA score or BSA score in a subject suffering from atopic dermatitis, the method comprising topically administering to the subject a Montelukast formulation comprising at least 1% (wt/wt) Montelukast or pharmaceutically acceptable salt thereof for at least 10 days, wherein the IGA score or the BSA score is reduced by at least 5% from placebo.
A stable topical formulation comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof;
Dependencies are inferred from the claim text.